tuneTypical Dose
600 to 1200 mg daily, often split, is common in pain studies
Compound
Palmitoylethanolamide
Palmitoylethanolamide
Evidence TierBWADA NOT PROHIBITED
watchEffect Window
Chronic-pain studies generally detect benefits over several weeks.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Palmitoylethanolamide has a meaningful evidence base for chronic pain reduction, especially neuropathic or mixed chronic-pain settings, but formulations matter.
PEA is one of the stronger modern supplement-adjacent pain compounds. Meta-analyses of randomized trials support a real pain-reduction effect, and newer trials using advanced formulations report clinically meaningful benefits in neuropathic low-back pain. The main limitation is formulation heterogeneity and the fact that much of the literature sits between supplement and medical-food territory.
PEA is an endogenous lipid mediator with anti-neuroinflammatory and analgesic properties. Human evidence is strongest in chronic pain, especially neuropathic or mixed pain states.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Reduction in chronic pain intensity
Secondary Outcomes
- Possible improvement in disability, sleep, and quality of life in neuropathic pain
Safety
Contraindications and Interactions
Contraindications
No entries provided
Side effects
- Mild GI symptoms
Interactions
No entries provided
Avoid if
- You are expecting immediate opioid-like pain relief
Evidence
Study-level References
pea-SRC-001Systematic review and meta-analysis
Sourceopen_in_newPaladini A, et al. Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials. J Clin Med. 2023. doi:10.3390/jcm12061350. PMID:36986081.
Population: Adults with chronic pain from double-blind randomized PEA trials.
Dose protocol: Mixed double-blind randomized PEA trials across chronic pain conditions
Key findings: Significant pain reduction in pooled analysis.
Notes: Best modern meta-analysis.
Paper content
This meta-analysis confirms that PEA has a meaningful chronic-pain evidence base across double-blind randomized trials.
pea-SRC-002Randomized controlled trial
Sourceopen_in_newPhospholipid-Based Delivery System Optimizes the Solubility and Systemic Exposure of Palmitoylethanolamide and Supports Clinical Benefits in Chronic Neuropathic Low Back Pain. 2024. PMID:41751279.
Population: Adults with chronic neuropathic low back pain.
Dose protocol: Phospholipid-based PEA 450 to 600 mg regimens for 8 weeks
Key findings: Significant improvement in multiple neuropathic low-back-pain outcomes versus placebo.
Notes: Best modern direct RCT.
Paper content
This trial is important because it shows that a modern high-bioavailability PEA formulation can improve multiple neuropathic low-back-pain outcomes compared with placebo.
pea-SRC-003Systematic review and meta-analysis of randomized clinical trials.
Sourceopen_in_newVina I, Lopez-Moreno M. Meta-Analysis of Palmitoylethanolamide in Pain Management: Addressing Literature Gaps and Enhancing Understanding. Nutr Rev. 2025;83:e1604-e1618. doi:10.1093/nutrit/nuae203. PMID:39798151.
Population: Adults with chronic pain across nociceptive, neuropathic, and nociplastic subtypes.
Dose protocol: 18 RCTs pooled across nociceptive, neuropathic, and nociplastic pain
Key findings: Significant pain reduction at 6 weeks (SMD -0.90), 8 weeks (SMD -0.98), and 24-26 weeks (SMD -1.16). Quality of life also improved (SMD -0.61). Effective across all pain subtypes.
Notes: Most comprehensive PEA pain meta-analysis to date (2025). Supersedes the 2017 Artukoglu analysis.
Paper content
This 2025 meta-analysis pooled 18 randomized clinical trials (1,196 patients) examining palmitoylethanolamide for pain management. PEA significantly reduced pain at 6 weeks (SMD -0.90), 8 weeks (SMD -0.98), and 24-26 weeks (SMD -1.16), with benefits across all pain types including nociceptive (SMD -0.74), neuropathic (SMD -0.97), and nociplastic pain (SMD -0.59). Quality of life also improved (SMD -0.61). The authors concluded that PEA effectively reduces pain and improves quality of life, with effects emerging within 4 to 6 weeks. This is the most comprehensive meta-analysis of PEA for pain to date, incorporating more recent trials than the 2017 Artukoglu meta-analysis.